Dionysios Neofytos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/942897/publications.pdf

Version: 2024-02-01

96 papers 5,585 citations

30 h-index 79644 73 g-index

98 all docs 98 docs citations 98 times ranked 6584 citing authors

#	Article	IF	CITATIONS
1	Epidemiology and outcomes of medically attended and microbiologically confirmed bacterial foodborne infections in solid organ transplant recipients. American Journal of Transplantation, 2022, 22, 199-209.	2.6	6
2	Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress?. Open Forum Infectious Diseases, 2022, 9, ofab596.	0.4	12
3	Impact of different urinary tract infection phenotypes within the first year post-transplant on renal allograft outcomes. American Journal of Transplantation, 2022, 22, 1823-1833.	2.6	15
4	Distribution of <i>Aspergillus</i> Species and Prevalence of Azole Resistance in Respiratory Samples From Swiss Tertiary Care Hospitals. Open Forum Infectious Diseases, 2022, 9, ofab638.	0.4	7
5	Frequency and causes of antifungal treatment changes in allogeneic haematopo $ ilde{A}$ -etic cell transplant recipients with invasive mould infections. Mycoses, 2022, 65, 199-210.	1.8	2
6	Central nervous system infections in solid organ transplant recipients: Results from the Swiss Transplant Cohort Study. Journal of Infection, 2022, 85, 1-7.	1.7	6
7	When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients?. Mycoses, 2022, 65, 1061-1067.	1.8	2
8	Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study. American Journal of Transplantation, 2021, 21, 2532-2542.	2.6	28
9	Invasive Aspergillosis Due to <i>Aspergillus</i> Section <i>Usti</i> : A Multicenter Retrospective Study. Clinical Infectious Diseases, 2021, 72, 1379-1385.	2.9	28
10	Burden, epidemiology, and outcomes of microbiologically confirmed respiratory viral infections in solid organ transplant recipients: a nationwide, multi-season prospective cohort study. American Journal of Transplantation, 2021, 21, 1789-1800.	2.6	23
11	Temporal trends, risk factors and outcomes of infections due to extended-spectrum \hat{l}^2 -lactamase producing Enterobacterales in Swiss solid organ transplant recipients between 2012 and 2018. Antimicrobial Resistance and Infection Control, 2021, 10, 50.	1.5	4
12	Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response. BMC Infectious Diseases, 2021, 21, 296.	1.3	24
13	Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study. Vaccines, 2021, 9, 372.	2.1	22
14	Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	5
15	Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. Medical Mycology, 2021, 59, 970-979.	0.3	20
16	Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in highâ€risk hematopoietic cell transplant recipients. Immunity, Inflammation and Disease, 2021, 9, 771-776.	1.3	13
17	Transplant infectious disease landscape in the COVID19-Era. Current Opinion in Infectious Diseases, 2021, Publish Ahead of Print, 273-274.	1.3	O
18	Differences Between Infectious Disease Events in First Liver Transplant Versus Retransplantation in the Swiss Transplant Cohort Study. Liver Transplantation, 2021, 27, 1283-1290.	1.3	3

#	Article	IF	CITATIONS
19	Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience. Mycopathologia, 2021, 186, 775-788.	1.3	5
20	COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it?. Clinical Microbiology and Infection, 2021, 27, 1376-1378.	2.8	33
21	Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey. Open Forum Infectious Diseases, 2021, 8, ofab471.	0.4	15
22	Screening for Parasitic Infection and Tuberculosis in Immunosuppressed and Pre-Immunosuppressed Patients: An Observational Study. Tropical Medicine and Infectious Disease, 2021, 6, 170.	0.9	3
23	Real-Life Considerations on Antifungal Treatment Combinations for the Management of Invasive Mold Infections after Allogeneic Cell Transplantation. Journal of Fungi (Basel, Switzerland), 2021, 7, 811.	1.5	2
24	Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 3020-3028.	1.3	5
25	Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients. Medical Mycology, 2021, 59, 701-711.	0.3	8
26	The EHA Research Roadmap: Infections in Hematology. HemaSphere, 2021, 5, e662.	1.2	5
27	Optimal Treatment Duration of Pseudomonas aeruginosa Infections in Allogeneic Hematopoietic Cell Transplant Recipients. Open Forum Infectious Diseases, 2020, 7, ofaa246.	0.4	7
28	Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland. Infection, 2020, 48, 761-766.	2.3	33
29	Combination Treatment With Letermovir and Ganciclovir for Maintenance Therapy of Multidrug-resistant CMV Infection in a Liver Transplant Recipient. Transplantation, 2020, 104, e248-e249.	0.5	8
30	First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study. American Journal of Transplantation, 2020, 20, 2876-2882.	2.6	102
31	Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm. Medical Mycology, 2020, 58, 1029-1036.	0.3	17
32	Risk factors for candidemia: a prospective matched case-control study. Critical Care, 2020, 24, 109.	2.5	92
33	Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5â€year analysis within the Swiss Transplant Cohort study. Transplant Infectious Disease, 2020, 22, e13289.	0.7	11
34	Response to "Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study― Blood Advances, 2020, 4, 420-421.	2.5	0
35	First case of Cryptococcus gattii multilobar pneumonia in Switzerland and associated challenges. Swiss Medical Weekly, 2020, 150, w20306.	0.8	0
36	Intracellular Pathogen in the Cerebrospinal Fluid of an Allogeneic Hematopoietic Cell Transplant Recipient With Graft-Versus-Host Disease and Brain Lesions. Clinical Infectious Diseases, 2020, 71, 3005-3008.	2.9	0

3

#	Article	IF	CITATIONS
37	1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients. Open Forum Infectious Diseases, 2020, 7, S660-S661.	0.4	O
38	Perspectives on <i>Scedosporium</i> species and <i>Lomentospora prolificans</i> in lung transplantation: Results of an international practice survey from ESCMID fungal infection study group and study group for infections in compromised hosts, and European Confederation of Medical Mycology. Transplant Infectious Disease, 2019, 21, e13141.	0.7	24
39	Antimicrobial Prophylaxis and Preemptive Approaches for the Prevention of Infections in the Stem Cell Transplant Recipient, with Analogies to the Hematologic Malignancy Patient. Infectious Disease Clinics of North America, 2019, 33, 361-380.	1.9	11
40	Substantial variation in the hepatitis B surface antigen (HBsAg) in hepatitis B virus (HBV)-positive patients from South Africa: Reliable detection of HBV by the Elecsys HBsAg II assay. Journal of Clinical Virology, 2018, 101, 38-43.	1.6	20
41	Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort Study. Transplant Infectious Disease, 2018, 20, e12898.	0.7	69
42	Detection of in vivo hepatitis B virus surface antigen mutationsâ€"A comparison of four routine screening assays. Journal of Viral Hepatitis, 2018, 25, 1132-1138.	1.0	10
43	<i>Pneumocystis jirovecii</i> pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort. Transplant Infectious Disease, 2018, 20, e12984.	0.7	39
44	Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS). Clinical Microbiology and Infection, 2018, 24, 1214.e1-1214.e4.	2.8	20
45	Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study. Transplant Infectious Disease, 2018, 20, e12981.	0.7	35
46	Efficacy of brincidofovir as prophylaxis against <scp>HSV</scp> and <scp>VZV</scp> in hematopoietic cell transplant recipients. Transplant Infectious Disease, 2018, 20, e12977.	0.7	19
47	Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy. Haematologica, 2018, 103, e527-e530.	1.7	26
48	First case of Candida auris in Switzerland: discussion about preventive strategies. Swiss Medical Weekly, 2018, 148, w14622.	0.8	28
49	Ultra-deep sequencing reveals high prevalence and broad structural diversity of hepatitis B surface antigen mutations in a global population. PLoS ONE, 2017, 12, e0172101.	1.1	24
50	Real-World Experience of Voriconazole Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: AASingle-Center Study. Open Forum Infectious Diseases, 2017, 4, S76-S77.	0.4	1
51	False-positive hepatitis C virus serology after placement of a ventricular assistance device. Transplant Infectious Disease, 2016, 18, 146-149.	0.7	6
52	Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. Transplantation, 2016, 100, e74-e80.	0.5	120
53	Cytomegalovirus Infection after CD34+-Selected Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1480-1486.	2.0	29
54	Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet, The, 2016, 387, 760-769.	6.3	695

#	Article	IF	CITATIONS
55	Paradoxical Effect of Donor Cytomegalovirus (CMV) Status on CMV Reactivation after T-Cell Depleted (TCD) Stem Cell Transplantation (SCT). Biology of Blood and Marrow Transplantation, 2015, 21, S302-S303.	2.0	O
56	Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin. Clinical Infectious Diseases, 2015, 61, S652-S661.	2.9	32
57	Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial. Transplant Infectious Disease, 2015, 17, 831-837.	0.7	12
58	Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis. PLoS ONE, 2015, 10, e0129022.	1.1	42
59	Target Enzyme Mutations Confer Differential Echinocandin Susceptibilities in Candida kefyr. Antimicrobial Agents and Chemotherapy, 2014, 58, 5421-5427.	1.4	13
60	A 70-Year-Old Kidney Transplant Recipient Presenting With Persistent Leg Cellulitis. Clinical Infectious Diseases, 2014, 59, 745-746.	2.9	2
61	A 70-Year-Old Kidney Transplant Recipient Presenting With Persistent Leg Cellulitis. Clinical Infectious Diseases, 2014, 59, 688-688.	2.9	0
62	Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance \hat{A}^{\otimes} registry. European Journal of Clinical Microbiology and Infectious Diseases, 2014, 33, 135-141.	1.3	22
63	Epidemiology of Candida kefyr in Patients with Hematologic Malignancies. Journal of Clinical Microbiology, 2014, 52, 1830-1837.	1.8	47
64	Donor-Derived Trypanosoma cruzi Infection in Solid Organ Recipients in the United States, 2001–2011. American Journal of Transplantation, 2013, 13, 2418-2425.	2.6	91
65	Clostridium difficile Infection after Adult Autologous Stem Cell Transplantation: A Multicenter Study of Epidemiology and Risk Factors. Biology of Blood and Marrow Transplantation, 2013, 19, 1502-1508.	2.0	38
66	Cunninghamella echinulata causing fatally invasive fungal sinusitis. Diagnostic Microbiology and Infectious Disease, 2013, 76, 506-509.	0.8	7
67	Epidemiology, outcomes, and risk factors of invasive fungal infections in adult patients with acute myelogenous leukemia after induction chemotherapy. Diagnostic Microbiology and Infectious Disease, 2013, 75, 144-149.	0.8	78
68	Epidemiology, risk factors, and outcomes of <i><scp>C</scp>lostridium difficile</i> infection in kidney transplant recipients. Transplant Infectious Disease, 2013, 15, 134-141.	0.7	42
69	Histoplasmosis and subcutaneous nodules in a kidney transplant recipient: erythema nodosum versus fungal panniculitis. Transplant Infectious Disease, 2013, 15, E58-63.	0.7	7
70	Detection of Cytomegalovirus DNA in Plasma as an Adjunct Diagnostic for Gastrointestinal Tract Disease in Kidney and Liver Transplant Recipients. Clinical Infectious Diseases, 2013, 57, 1550-1559.	2.9	63
71	Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10â€year, singleâ€center experience. Transplant Infectious Disease, 2013, 15, 233-242.	0.7	120
72	Administration of Voriconazole in Patients With Renal Dysfunction. Clinical Infectious Diseases, 2012, 54, 913-921.	2.9	53

#	Article	IF	CITATIONS
73	Epidemiology and Outcomes of Clostridium difficile Infections in Hematopoietic Stem Cell Transplant Recipients. Clinical Infectious Diseases, 2012, 54, 1053-1063.	2.9	196
74	Actinomucor elegans as an Emerging Cause of Mucormycosis. Journal of Clinical Microbiology, 2012, 50, 1092-1095.	1.8	25
75	Diagnostic and therapeutic challenges in a liver transplant recipient with central nervous system invasive aspergillosis. Diagnostic Microbiology and Infectious Disease, 2012, 73, 374-375.	0.8	4
76	The PATH (Prospective Antifungal Therapy) Alliance \hat{A}^{\otimes} registry and invasive fungal infections: update 2012. Diagnostic Microbiology and Infectious Disease, 2012, 73, 293-300.	0.8	202
77	An outbreak of human parainfluenza virus 3 infection in an outpatient hematopoietic stem cell transplantation clinic. American Journal of Infection Control, 2012, 40, 601-605.	1.1	23
78	Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004–2008. Diagnostic Microbiology and Infectious Disease, 2012, 74, 323-331.	0.8	335
79	Donorâ€derived organ transplant transmission of coccidioidomycosis. Transplant Infectious Disease, 2012, 14, 300-304.	0.7	49
80	Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients. Transplant Infectious Disease, 2010, 12, 220-229.	0.7	382
81	Chest Computed Tomography versus Serum Galactomannan Enzyme Immunoassay for the Diagnosis of Probable Invasive Aspergillosis: To Be Decided. Clinical Infectious Diseases, 2010, 51, 1281-1283.	2.9	9
82	Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry. Clinical Infectious Diseases, 2009, 48, 1695-1703.	2.9	809
83	Reply to Pagano et al Clinical Infectious Diseases, 2009, 48, 1801-1803.	2.9	1
84	Epidemiology and Outcome of Invasive Fungal Infection in Adult Hematopoietic Stem Cell Transplant Recipients: Analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance Registry. Clinical Infectious Diseases, 2009, 48, 265-273.	2.9	694
85	Peripheral Subcutaneous Stimulation for the Treatment of Intractable Postherpetic Neuralgia: Two Case Reports and Literature Review. Pain Practice, 2009, 9, 225-229.	0.9	34
86	Aspergillus osteomyelitis: review of 12 cases identified by the Prospective Antifungal Therapy Alliance registry. Diagnostic Microbiology and Infectious Disease, 2009, 63, 384-387.	0.8	32
87	Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagnostic Microbiology and Infectious Disease, 2009, 64, 152-157.	0.8	39
88	Epidemiology and outcome of multiple-species candidemia at a tertiary care center between 2004 and 2007. Diagnostic Microbiology and Infectious Disease, 2009, 64, 289-294.	0.8	27
89	Candidemia in the 21st century. Future Microbiology, 2008, 3, 463-472.	1.0	33
90	Stem Cell Transplant Recipient With Multiple Skin Lesions. Infectious Diseases in Clinical Practice, 2007, 15, 111-112.	0.1	0

#	Article	IF	CITATIONS
91	Treatment of Adenovirus Disease in Stem Cell Transplant Recipients with Cidofovir. Biology of Blood and Marrow Transplantation, 2007, 13, 74-81.	2.0	148
92	Presentation of the PATH Alliance \hat{A}^{\odot} registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagnostic Microbiology and Infectious Disease, 2007, 59, 407-414.	0.8	81
93	Emergence of Staphylococcal Cassette Chromosome <i>mec</i> Type IV Methicillin-Resistant <i>Staphylococcus aureus</i> as a Cause of Ventilator-Associated Pneumonia. Infection Control and Hospital Epidemiology, 2007, 28, 1206-1209.	1.0	7
94	Use of the PATH Alliance database to measure adherence to IDSA guidelines for the therapy of candidemia. European Journal of Clinical Microbiology and Infectious Diseases, 2007, 26, 907-914.	1.3	18
95	Rhodotorula mucilaginosa Catheter-related Fungemia in a Patient with Sickle Cell Disease: Case Presentation and Literature Review. Southern Medical Journal, 2007, 100, 198-200.	0.3	19
96	A case of recurrent episodes of Candida parapsilosis fungemia. Mycopathologia, 2006, 162, 295-298.	1.3	6